Treatment and diagnosis progress of chronic myeloid leukemia
10.3760/cma.j.cn115356-20200207-00034
- VernacularTitle:慢性粒细胞白血病诊治进展
- Author:
Peifang JIANG
1
;
Luting LUO
;
Jianda HU
Author Information
1. 福建医科大学附属协和医院血液科 福建省血液病学重点实验室 福建省血液病研究所，福州 350001
- From:
Journal of Leukemia & Lymphoma
2020;29(4):202-205
- CountryChina
- Language:Chinese
-
Abstract:
The identification of BCR-ABL fusion gene and the advent of tyrosine kinase inhibitors (TKI) targeting this mutation have promoted the landmark progress of diagnosis and treatment in chronic myeloid leukemia (CML), and have dramatically changed the treatment management and disease prognosis for CML patients. Most of the western countries hold a view that CML is cut and dried, but the situation is not the same in developing countries. Currently, more attention is paid to the discontinuation of TKI. In addition, deep challenges remain in the low- and middle-income countries. This paper reviews the treatment progress of CML and challenges in low-and middle-income countries reported at the 61st American Society of Hematology Annual Meeting.
